Expedition 369 methods

This chapter documents the procedures and methods used in the shipboard laboratories during International Ocean Discovery Program (IODP) Expedition 369. This introductory section in particular provides a rationale for the site locations and an overview of IODP depth conventions, curatorial procedures, and general core handling/analyses during Expedition 369. Subsequent sections describe specific laboratory procedures and instruments in more detail. This information only applies to shipboard work described in the Proceedings volume; methods used in shore-based analyses of Expedition 369 samples and/or data will be described in various scientific contributions in the open peer-reviewed literature and the Expedition Research Results chapters of this Proceedingsvolume

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Late Cretaceous stratigraphy and paleoceanographic evolution in the Great Australian Bight Basin based on results from IODP Site U1512

International audienceThe Upper Cretaceous sedimentary sequence at International Ocean Discovery Program Site U1512 in the Ceduna Sub-basin of the Great Australian Bight represents a continuous, > 690 m thick interval of black silty clay and claystone spanning the lower Turonian through Lower Campanian (~10 million years). Sediments were deposited in an elongate, ~E-W oriented, ~2500 km long rift system that developed between Australia and Antarctica with an open-ocean connection to the west and a continental bridge to the east. Site U1512 cores provide a unique, continuous record of Late Cretaceous deposition in the Ceduna Sub-basin on the hanging wall of the Wallaroo Fault Zone. Study of U1512 samples could provide both an important high-latitude, southern hemisphere perspective on climatic evolution during the peak and demise of the Cretaceous hothouse and an offshore record of the sedimentation history in the basin during the Late Cretaceous portion of the Gondwanan breakup. The Upper Cretaceous sequence at Site U1512 is notable for its lithologic uniformity. Burrow-mottled to massive claystone and silty claystone make up the majority of the almost 700 m section, while rare (n = 28) isolated, 2 to 21 cm thick medium to fine sandstone beds are a minor lithology. Macrofossils present include common inoceramids and rare occurrences of other bivalves and ammonites. Microfossils include common occurrences of calcareous nannofossils, agglutinated and calcareous benthic foraminifera, radiolaria and organic-walled dinoflagellate cysts as well as rare small, surface dwelling planktonic foraminifera. Carbonate (<7%) and organic carbon (<1.5%) contents are low. Despite the lithologic uniformity, rhythmic alternations in the intensity of magnetic susceptibility and natural gamma radiation are well-resolved in much of the recovered section and continue through minor coring gaps (as documented by downhole logs). Data from Site U1512 provide new perspectives on our understanding of the deep-water frontier region between Antarctica and Australia